Drugs / Pertagen
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02946190 | Oct 2016 → Mar 2017 | pertussis | University Hospital, Geneva | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05193734 | Feb → Aug 2022 | pertussis | University Hospital, Geneva | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06798831 | Feb → Apr 2025 overdue | — | BioNet-Asia Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06803524 | May 2025 → Mar 2026 overdue | pertussis | Mahidol University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pertagen | “This pivotal safety trial aims to extend the safety database for BioNet recombinant acellular pertussis (aP) vaccine (Pertagen®) in a larger population of adults and evaluate...” NCT06798831 ↗ |
| Known as | BioNet recombinant acellular pertussis (aP) vaccine | “This pivotal safety trial aims to extend the safety database for BioNet recombinant acellular pertussis (aP) vaccine (Pertagen®) in a larger population of adults and evaluate...” NCT06798831 ↗ |
| Modality | Vaccine | “The BioNet-Asia study vaccine (Pertagen®)” NCT02946190 ↗ |
| Route | Intramuscular | “All vaccines are presented in 0.5 mL pre-filled syringes to be administered by intramuscular injection.” NCT02946190 ↗ |